-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Berkeley Lights (Nasdaq: BLI), a leading life sciences company, and single-cell proteomics expert IsoPlexis (Nasdaq:
ISO) recently announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis
in an all-stock transaction.
Berkeley
Headquartered in Emeryville, California, Lights is a leading digital cell biology company
focused on single-cell functional characterization solutions.
Based on proprietary light guide technology and nano-microfluidic technology, BLI provides scientists with the most advanced research environment to conduct in-depth characterization of the genetic information and function of tens of thousands of single cells to screen out the target cells
that meet the needs of users 。 Berkeley
Since its launch in 2016, Lights' single-cell light guide platform has more than 100 users around the world, covering infectious disease research, emergency medicine, cell line development, vaccine production, immunology research and cell therapy development, gene editing, tumor biology research, stem cell function characterization, gene therapy development, synthetic biology and agricultural science, providing unprecedented opportunities to engage in cutting-edge scientific research projects and accelerate the development of enterprise biological products
。
After the acquisition, Berkeley
Lights and IsoPlexis will merge to form a new company
called PhenomeX (Nasdaq: CELL).
As a leading explorer of functional cell biology, PhenomeX will bring together innovative solutions from both companies and a global team that complements our corporate culture and business capabilities, and through its leading technology in functional cell biology, it will provide researchers with live-cell biology research tools, presenting in-depth insights into cell function and new perspectives
on various research phenomena.
The acquisition is expected to close
in the first quarter of 2023.
Until the acquisition closes, Berkeley Lights and IsoPlexis will continue to operate
as two separate companies.
Since IsoPlexis entered China, it has received strong support from customers and partners! We will adhere to the original intention of serving Chinese customers, continue to provide you with high-quality single-cell functional protein detection solutions, and jointly explore superheroes in single-cell cells!
Original English: https://endpts.
com/berkeley-lights-to-acquire-isoplexis-in-57-8m-all-stock-deal/
com/berkeley-lights-to-acquire-isoplexis-in-57-8m-all-stock-deal/